Source: Merck and Pfizer announced recently that the FDA of the United States has accepted the review of three new drug applications (NDA) containing ertugliflozin
MSD's US $1.25 billion acquisition of African Pharma
Time of Update: 2016-06-13
According to MSD, African Pharma has initiated the clinical development of innovative drugs targeting P2X3 receptor selectively, which is an exciting research field.
Perjury? MSD and Gilead patent lawsuits have changed!
Time of Update: 2016-05-05
Source: Medical Rubik's cube data 2016-05-04 a jury of a federal court in the United States announced on March 22 that it supported the judge's judgment, finding that the two
MSD's disclosure of keytruda's clinical survival data has intensified its competition with opdivo
Time of Update: 2015-12-22
Anderson also mentioned that both opdivo and keytruda are anti-PD-1 / PD-L1 immunotherapy drugs, which have similar clinical effects on PD-L1 positive patients, are superior to traditional chemotherapy, and have similar safety data.
MSD and kangfang biology announced an important cooperation in the field of tumor immunotherapy
Time of Update: 2015-12-04
Source: Biovalley 2015-12-04 (December 4, 2015, Zhongshan, Guangdong Province, China), Zhongshan kangfang biomedical Co., Ltd
(hereinafter referred to as "kangfang
Drug pricing: the US government investigates Lilly and MSD
Time of Update: 2015-11-17
Source: on November 17, 2015, both Merck & Co and Eli Lilly disclosed that the company was under investigation by the U.S
Department of justice
As a result
Opdivo of BMS beat keytruda of MSD for the first time in Q3 2015
Time of Update: 2015-10-30
Source: on October 30, 2015, both Bristol Myers Squibb and MSD announced the company's sales in the third quarter
The sales data showed that the sales of opdivo, the PD
MSD and MD Anderson reach strategic cooperation in tumor immunology
Time of Update: 2015-08-14
Source: Biovalley, August 14, 2015 Merck & Co, the US pharmaceutical giant, recently entered into a strategic clinical research cooperation with MD Anderson Cancer Center
Elgin's $250 million purchase of MSD CGRP migraine new drug project
Time of Update: 2015-07-08
The project includes two small oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are currently being developed for the treatment and prevention of migraine.
Novo Nordisk, Sanofi and MSD dominate the global diabetes drug market
Time of Update: 2015-06-29
Novo Nordisk, Sanofi and MSD are leading the pack with strong earnings from diabetes medicine products as these companies win in this rapidly growing global market.
Gilead's match! MSD will fight the battle of hepatitis C therapy again!
Time of Update: 2015-04-24
Source: Biovalley April 24, 2015 hepatitis C has always been one of the diseases that the biomedical industry focuses on, and Gilead has become the biggest winner in this field
MSD and syndex reach cooperation on "breakthrough" cancer compound drugs
Time of Update: 2015-04-08
Source: will the combination of two breakthrough cancer drugs of Ding Xiangyuan 2015-04-07 be better than one drug? In a phase 1B / 2 study, drug giant MSD and syndax of Waltham
Battle for melanoma Market: keysruda of MSD beat yervoy of BMS
Time of Update: 2015-04-02
Ling fengmuyun: Doctor of pharmaceutical chemistry, Sichuan University, once worked as a special editor on the website of "mystery of life", and won the "best exhibition Report
MSD plans to share children's AIDS drugs in the patent pool of non-profit organizations
Time of Update: 2015-02-26
Two months ago, the non-profit drug patent pool (MPP) signed a cooperation license with lopinavir and ritonavir, two other AIDS drugs for children.
MSD completed the acquisition of cupist, an antibiotic giant, with us $9.5 billion
Time of Update: 2015-01-22
Source: Biovalley on January 22, 2015, MSD recently announced that it has successfully completed the acquisition of all outstanding common shares of antibiotic giant Cubist at US $102 per share.
Moderna signed another $100 million RNA drug development agreement with MSD
Time of Update: 2015-01-14
And one of the sharp tools that Moderna company is so favored by MSD is the technology of delivering RNA medicine developed by the company.
MSD's $375 million acquisition of oncoethix to further expand oncology assets
Time of Update: 2014-12-19
Through this acquisition, mosadon obtained the experimental drug otx015 of oncoethix company, which is a bet (bromer domain) inhibitor, aiming to trigger cancer cell death by targeting the protein 2 / 3 / 4 of the bet bromer domain.
FDA Approves Gardasil 9, a super HPV vaccine from MSD, with a peak sales of $1.9 billion
Time of Update: 2014-12-12
Source: Biovalley, Dec
11, 2014 Merck & Co has received great news recently
Gardasil 9, the successor of Gardasil, has been approved by FDA
MSD announces $9.5 billion acquisition of pharmaceutical company Cubist
Time of Update: 2014-12-10
Source: US stock Tencent Finance on the evening of December 8, 2014 Beijing time, MSD and pharmaceutical company Cubist pharmaceuticals announced today that they have reached a final deal agreement.